CystitisMANAGEMENT

GENITOURINARY AND REPRODUCTIVE PRESENTATIONS · 12 SECTIONS

⚲

656 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Acute Kidney Injury (ATN)Acute Kidney Injury (Post-renal)Acute Kidney Injury (Pre-renal)Amniotic Fluid Embolism Balanitis Bladder Rupture Breast Abscess Cystitis Dialysis access complications Ectopic pregnancy Epididymitis Glomerulonephritis Hematuria (gross)Hydrocele Interstitial Cystitis Mastitis Mittelschmerz Nephrolithiasis Nephrotic Syndrome Flare Nutcracker Syndrome Orchitis Ovarian Cyst Rupture Ovarian hyperstimulation syndrome Ovarian torsion Paraphimosis Pelvic Congestion Syndrome Pelvic Inflammatory Disease (PID)Peritoneal dialysis peritonitis Phimosis Priapism Prostatitis Pyelonephritis Renal laceration Renal transplant complications and rejection Ruptured ovarian cyst Testicular torsion Torsion of Appendix Testis Tubo-ovarian abscess Ureteral Rupture Urethritis Urinary Retention Urinary tract infection (uncomplicated)Urolithiasis (renal colic)Vaginal bleeding (non-pregnant)Vaginitis (Bacterial)Vaginitis (Candidal)Varicocele Vulvovaginal Hematoma

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp27

Sepsis and urosepsis identification

›Urosepsis triggers

›Temperature >38°C or <36°C with urinary source

›Hemodynamic instability requires immediate action

›Septic shock: SBP <90 mmHg or MAP <65 mmHg despite fluid resuscitation

›Altered mental status with urinary symptoms

›Especially in elderly or immunocompromised patients

›Lactate >=2 mmol/l supports organ hypoperfusion

›Tachycardia with urinary source

›HR >100 with fever or hypotension

›Concurrent tachypnea (RR >22)

Immediate stabilization

›Fluid resuscitation targets

›IV access and crystalloid bolus if hypotensive

›30 mL/kg lactated Ringer's or normal saline for septic shock

›Reassess fluid responsiveness after each bolus

›Vasopressor initiation if refractory hypotension

›Norepinephrine 0.01-0.3 mcg/kg/min titrated to MAP >65 mmHg

›First-line vasopressor in septic shock

Escalation and consult triggers

›Indications for urgent intervention

›Suspected emphysematous cystitis or pyelonephritis

›Diabetic patient with urinary symptoms and severe toxicity

›CT abdomen/pelvis emergently

›Suspected urinary obstruction

›Urinary retention with inability to void

›Bladder decompression via catheterization

›Complicated UTI with sepsis physiology

02History/hx71

Presenting symptoms

›Core urinary symptoms

›Dysuria (burning or pain with urination)

›Internal dysuria favors cystitis

›External dysuria favors vulvovaginitis or herpes

›Urinary frequency and urgency

›Increased voiding episodes per day

›Urgency with or without urge incontinence

›Suprapubic pain or pressure

›Worsened with bladder filling

›Distinct from flank or CVA pain

›Gross hematuria

›Pink, red, or cola-colored urine

›Clots suggest more severe mucosal involvement

›Nocturia and incomplete emptying sensation

Important negatives and differentiating features

›Features that lower cystitis probability

›Vaginal discharge or odor

›Raises probability of vaginitis or STI

›Absence of discharge raises UTI probability to >90% with dysuria and frequency

›Vaginal itching or vulvar lesions

›Candidal vaginitis or genital herpes consideration

›Urethral discharge in men

›Urethritis or gonorrhea/chlamydia

›Features that suggest upper tract involvement

›Fever >38°C

›Pyelonephritis rather than uncomplicated cystitis

›Rigors or chills indicate bacteremia risk

03Physical Exam/exam52

Vital signs

›Hemodynamic and temperature assessment

›Temperature

›>38°C suggests pyelonephritis or complicated UTI

›Hypothermia (<36°C) indicates severe sepsis

›Heart rate

›Tachycardia >100 with urinary symptoms indicates systemic involvement

›Blood pressure

›SBP <90 mmHg or MAP <65 mmHg as urosepsis indicators

›Respiratory rate

›>22 breaths/min with urinary source as sepsis criterion

›Oxygen saturation

›Baseline for monitoring in systemically unwell patients

Abdominal and pelvic exam

›Abdomen

›Suprapubic tenderness

›Supports lower urinary tract infection

›Absent in uncomplicated cases or with subtle infection

›Suprapubic distension

›Urinary retention requiring decompression

›Abdominal guarding or rebound

›Raises concern for alternative intraabdominal pathology

›Costovertebral angle exam

›CVA tenderness

›Only physical exam finding that increases UTI probability

›Specifically indicates upper tract involvement (pyelonephritis)

›Percussion technique

›Fist percussion over costovertebral angle bilaterally

04Differential Diagnosis/ddx35

Life-threatening diagnoses

›Immediate threats to exclude

›Urosepsis progressing to septic shock

›ICD-10 A41.51 (sepsis due to E. coli)

›Requires emergent antibiotics, fluids, vasopressors

›Emphysematous cystitis or pyelonephritis

›Gas-forming organisms in diabetic or immunocompromised patients

›CT diagnosis; surgical or interventional urology consultation

›Renal abscess or perinephric abscess

›Failed antibiotic therapy with persistent fever

›Drainage required

Common mimics

›Pyelonephritis

›ICD-10 N10 (acute pyelonephritis)

›Differentiating: fever, flank pain, CVA tenderness, systemic illness

›Vaginitis

›Candidal, bacterial vaginosis, trichomonal

›Differentiating: vaginal discharge, external dysuria, absence of frequency/urgency

›Urethritis and STI

›ICD-10 A54.01 (gonorrhea), A56.01 (chlamydia)

›Differentiating: urethral/cervical discharge, gradual onset, STI risk factors

›Interstitial cystitis/bladder pain syndrome

›ICD-10 N30.10

›Differentiating: chronic/recurrent symptoms, pain relieved by voiding, negative cultures

Other differentials

›Urologic and structural causes

›Nephrolithiasis

›ICD-10 N20.0

05Laboratory Tests/lt55

Urinalysis

›Urine dipstick

›Leukocyte esterase

›Sensitivity 81-83%, specificity 67-71%

›Reflects pyuria; surrogate for WBC in urine

›Nitrites

›Sensitivity 55-58%, specificity 90-98%

›Produced by gram-negative organisms reducing dietary nitrates

›False negative if organism does not reduce nitrates (Enterococcus, Pseudomonas, Staph)

›Combined leukocyte esterase or nitrite positive

›Sensitivity 75%, specificity 82%

›If both negative, UTI is unlikely (NPV 78-98%)

›Hematuria on dipstick

›Present in 40-60% of UTI cases; not diagnostic alone

›Urine microscopy

›Pyuria (>10 WBC/hpf)

›Supports urinary tract infection diagnosis

›Can be absent in early or dilute samples

›Bacteriuria on unspun sample

›Any bacteria correlates with >100,000 CFU/mL if catheterized specimen

›RBCs

›Hematuria supports cystitis; persistent post-treatment warrants further workup

Urine culture

›Indications and interpretation

›NOT required for uncomplicated cystitis in women with classic symptoms

›Positive culture defined as >=10^5 CFU/mL of uropathogen in clean catch

›Lower threshold of >=10^3 CFU/mL for catheterized specimens

›Indications for urine culture

06Diagnostic Tests/dt58

Scoring Systems

›Clinical probability estimation

›Symptom-based probability for uncomplicated cystitis in women

›Dysuria + frequency without vaginal discharge: probability >90%

›Classic triad (dysuria, frequency, urgency) without alarm features: treat empirically

›Ann Arbor UTI Triage Guide (2026, JAMA Network Open)

›Stratifies into telephone management, telehealth, or in-person evaluation

›Telephone management: classic symptoms, no complicating factors, no alarm signs

›In-person required: men, pregnancy, recurrent UTI, systemic symptoms, urinary obstruction

›ACEP Level B recommendation: empiric treatment without culture for classic uncomplicated UTI in women

Scoring Systems for Severity

›Sepsis severity tools

›qSOFA (quick Sepsis-related Organ Failure Assessment)

›Altered mental status, RR >=22, SBP <=100 mmHg

›Score >=2 suggests sepsis; obtain full SOFA

›SOFA score components for organ failure quantification

›Respiratory, coagulation, liver, cardiovascular, CNS, renal

›Score >=2 above baseline confirms sepsis criteria

MRI

›MRI indications in cystitis

›Not routinely indicated for uncomplicated cystitis

›No role in standard acute management

›MRI pelvis for recurrent cystitis workup

›Bladder wall thickening or irregularity on T2

›Exclusion of fistula (vesicovaginal, colovesical)

›Detection of adjacent pelvic pathology

›MRI urography for structural abnormalities

›Preferred over CT in pregnancy for upper tract evaluation

07Disposition/dispo45

Discharge criteria

›Uncomplicated cystitis discharge

›Classic UTI symptoms in non-pregnant adult women

›No fever, no flank pain, no systemic illness

›Able to tolerate oral medications

›Oral antibiotic prescription with clear return precautions

›Symptoms expected to improve within 24-48 hours

›Routine follow-up not needed if symptoms resolve

›Vast majority of cystitis cases managed entirely as outpatient

›ACEP and IDSA guidelines support outpatient management

Admission indications

›Criteria requiring hospital admission

›Urosepsis or septic shock

›Hemodynamic instability despite initial resuscitation

›ICU-level care for vasopressor-dependent patients

›Intractable nausea/vomiting preventing oral antibiotic administration

›IV antibiotic therapy required

›Severe pyelonephritis with systemic toxicity

›High fever with rigors, dehydration, clinical deterioration

›Immunocompromised patient with systemic illness

›Transplant, neutropenia, HIV with low CD4

›Pregnant patient with pyelonephritis

›All pregnant patients with upper tract infection require admission

›Emphysematous cystitis or pyelonephritis

›Surgical or interventional urology consultation

Transfer and consultation

›Consultation triggers

›Urology referral (non-urgent)

08Treatment/t111

First-line antibiotics for uncomplicated cystitis in women

›Nitrofurantoin

›Dose: 100 mg BID x 5 days (modified-release formulation)

›Highest clinical cure rate in recent network meta-analysis

›74% clinical resolution rate in SCOUT trial (2026, Lancet)

›Contraindications

›CrCl <30 mL/min: inadequate urinary concentration

›Not effective for upper tract infections (poor renal parenchymal penetration)

›Avoid in G6PD deficiency

›Avoid at term pregnancy (38-42 weeks: hemolytic anemia risk in neonate)

›Cautions

›Pulmonary toxicity with prolonged use (>6 months)

›Peripheral neuropathy with chronic use in renal impairment

›TMP-SMX (trimethoprim-sulfamethoxazole)

›Dose: 160/800 mg BID x 3 days

›Use only if local E. coli resistance <20%

›IDSA/ACP guideline-recommended first-line agent

›Contraindications

›Sulfa allergy

›First trimester pregnancy (folate antagonism) and near term (kernicterus risk)

›Severe renal or hepatic impairment

›Drug interactions

›Warfarin: significantly increased INR

›Methotrexate: increased toxicity

›Fosfomycin

›Dose: 3 g single dose oral sachet

›Inferior to nitrofurantoin per SCOUT trial (2026, Lancet)

›Useful when other agents contraindicated or unavailable

›Contraindications and limitations

›Not effective for ESBL Klebsiella pneumoniae (carries fosA gene)

›Limited data for complicated UTI

›Pivmecillinam

›Dose: 400 mg TID x 3 days

›FDA-approved in the US for uncomplicated UTI in women >=18 years

›70% clinical resolution rate

›Mechanism: extended-spectrum aminopenicillin (PBP2 binding)

›Active against ESBL-producing organisms in some cases

Antibiotics to avoid

›Agents not recommended empirically for uncomplicated cystitis

›Fluoroquinolones (ciprofloxacin, levofloxacin)

›Not recommended due to adverse effect profile

›Tendinopathy and tendon rupture risk

›QTc prolongation risk

›Aortic dissection risk with prolonged use

›C. difficile risk

›Reserve for resistant organisms confirmed on culture

›IDSA Class III recommendation against empiric fluoroquinolone use

›Beta-lactams (amoxicillin, amoxicillin-clavulanate)

›High E. coli resistance rates

›Lower efficacy than preferred agents

›Consider only if preferred agents contraindicated

Symptomatic relief

›Analgesic and anti-spasmodic therapy

›Phenazopyridine 200 mg TID x 2 days

›Urinary analgesic only; no antimicrobial activity

›Warn patient: orange/red urine discoloration is expected

›Not for use >2 days (masks symptoms of untreated infection)

›NSAIDs for pain management

›Ibuprofen 400 mg TID for suprapubic pain relief

›Cochrane 2024: NSAIDs alone inferior to antibiotics; not recommended as monotherapy

Treatment for complicated cystitis and special situations

›Complicated UTI antibiotic selection

›Empiric coverage pending culture

›Cephalexin 500 mg QID x 7 days for low-resistance settings

›Amoxicillin-clavulanate 875/125 mg BID x 5-7 days

›ESBL-producing organisms (culture-guided)

›Nitrofurantoin if susceptible and lower tract only

›Ertapenem 1 g IV once daily for systemic or upper tract ESBL

›IDSA 2023 guidance on AMR gram-negative infections

›Catheter-associated UTI (CAUTI)

›Remove or replace catheter before initiating antibiotics

›7-day course for women, 7-14 days for men

›Culture-directed therapy required

›Male UTI treatment

›TMP-SMX 160/800 mg BID x 7 days

›Urine culture always required in men

›Prostatitis excluded before shorter course

›Nitrofurantoin 100 mg BID x 7 days if TMP-SMX unsuitable

Intravenous therapy for severe or complicated presentations

›Parenteral antibiotic options

›Ceftriaxone 1-2 g IV once daily

›First-line IV agent for acute pyelonephritis

›Adjust based on culture and sensitivity results

›Piperacillin-tazobactam 3.375 g IV q6h or 4.5 g IV q8h

›Broad-spectrum coverage for complicated or healthcare-associated UTI

›Covers Pseudomonas in structural lung disease patients

›Ertapenem 1 g IV once daily

›ESBL-producing organisms in severe infection

›Meropenem 1 g IV q8h

›Carbapenem-resistant Enterobacterales requires ID consultation

›Gentamicin 5-7 mg/kg IV once daily

›Renal function monitoring required

›Trough <1 mg/L before next dose

Recurrence prevention

›Non-antibiotic preventive strategies

›Hydration >=1.5 L per day

›Most evidence-supported dietary intervention

›Reduces catheter-associated UTI risk

›Cranberry products

›Role in prevention of recurrent UTI (not acute treatment)

›Modest evidence; safe to recommend

›Methenamine hippurate 1 g BID

›Effective for recurrent UTI prevention in low-risk patients

›Not for patients with renal impairment or severe hepatic disease

›Topical vaginal estrogen in postmenopausal women

›Restores lactobacilli and reduces recurrence

›Estriol cream or vaginal estradiol ring

›Antibiotic prophylaxis strategies

›Post-coital single-dose prophylaxis

›TMP-SMX 40/200 mg or nitrofurantoin 50-100 mg within 2 hours of intercourse

›Continuous low-dose prophylaxis (for >=3 UTI/year)

›Nitrofurantoin 50-100 mg at bedtime

›TMP-SMX 40/200 mg at bedtime

›Duration typically 6-12 months

›Patient-initiated therapy (backup prescription)

›For low-risk women who prefer to avoid routine antibiotics

›Fill if symptoms do not improve in 48-72 hours

09Special Populations/sp73

Pregnancy

›Unique considerations in pregnancy

›Asymptomatic bacteriuria requires treatment in pregnancy

›2-10% prevalence in pregnant women

›If untreated, 25-30% progress to pyelonephritis

›Screening with urine culture at first prenatal visit recommended

›Risk of adverse outcomes with untreated UTI

›Preterm labor

›Low birth weight

›Intrauterine growth restriction

›ACOG 2023 consensus: all UTIs require culture-confirmed diagnosis and treatment

›Antibiotic selection in pregnancy

›Safe first-line agents

›Nitrofurantoin 100 mg BID x 5 days (avoid at 38-42 weeks)

›Amoxicillin-clavulanate 875/125 mg BID x 5-7 days if susceptible

›Cephalexin 500 mg QID x 5-7 days

›Agents to avoid in pregnancy

›TMP-SMX: folate antagonism in first trimester; kernicterus risk near term

›Fluoroquinolones: fetal cartilage damage; avoid throughout pregnancy

›Nitrofurantoin at 38-42 weeks: neonatal hemolytic anemia risk

›Test-of-cure culture required 1-2 weeks after treatment completion

›Recurrence common; repeat screening each trimester

›Pyelonephritis in pregnancy

›Hospital admission required for all pregnant patients with pyelonephritis

›Ceftriaxone 1-2 g IV once daily until afebrile 24-48 hours

›Transition to oral therapy based on culture results

›Suppressive therapy for remainder of pregnancy after pyelonephritis

Geriatric

›Diagnostic challenges in older adults

›Atypical presentations common

›New confusion or delirium may be the only symptom in frail elderly

›Functional decline without classic urinary symptoms

›Falls, anorexia, or worsening baseline function

›Asymptomatic bacteriuria is common and should NOT be treated

›Prevalence 10-50% in institutionalized elderly

›Antibiotic overtreatment increases C. difficile risk and resistance

›Classic urinary symptoms required before initiating antibiotics

›Polypharmacy and drug interactions

›TMP-SMX raises potassium (hyperkalemia risk with ACE inhibitors, ARBs)

›Nitrofurantoin requires adequate CrCl (avoid if <30 mL/min)

›Fluoroquinolones increase tendon rupture and QTc risk

›Management modifications in elderly

›Renal function assessment mandatory before antibiotic selection

›Age-related decline in GFR affects nitrofurantoin and TMP-SMX dosing

›Genitourinary syndrome of menopause as underlying predisposing factor

›Topical vaginal estrogen reduces recurrence rate

›Lower threshold for urine culture in elderly

›Resist antibiotic pressure without objective evidence of infection

Pediatrics

›Unique considerations in children

›UTI epidemiology in children

›More common in boys <1 year (uncircumcised)

›More common in girls after 1 year

›8% of girls and 2% of boys have UTI by age 7

›Risk of renal scarring

›Vesicoureteral reflux (VUR) predisposes to recurrent pyelonephritis

›Renal scarring leads to hypertension and chronic kidney disease

›Imaging to detect VUR indicated after first febrile UTI in young children

›Presentation in children

›Neonates and infants (<2 years)

›Fever without source is most common presentation

›Irritability, poor feeding, vomiting, failure to thrive

›Catheterized or suprapubic aspirate urine sample required

›Older children (>2 years)

›Classic symptoms similar to adults: dysuria, frequency, urgency

›School-age girls: new-onset enuresis may indicate UTI

›Antibiotic selection in children

›Cephalexin 25-50 mg/kg/day divided TID-QID x 7-10 days (oral, first-line)

›Widely used and effective for pediatric UTI

›TMP-SMX 8/40 mg/kg/day divided BID x 7-10 days if susceptible

›Check local resistance patterns

›Nitrofurantoin 5-7 mg/kg/day divided QID x 5 days

›Avoid in children <1 month (hemolytic anemia risk)

›Avoid if CrCl impaired

›Ceftriaxone 50-75 mg/kg/day IV or IM once daily for pyelonephritis

›Febrile UTI or failed oral treatment

10Background/b74

Epidemiology

›Prevalence and incidence

›Cystitis is one of the most common bacterial infections in ambulatory care

›150 million cases per year worldwide

›11% of women report at least one UTI per year in the US

›40-50% of women experience at least one UTI in their lifetime

›Gender distribution

›Female:male ratio approximately 50:1 due to anatomical differences

›Short female urethra (3-4 cm) vs male urethra (20 cm)

›Lifetime prevalence in men is 12% (most cases are complicated)

›Recurrence rates

›25-30% of women have a second UTI within 6 months

›Recurrent UTI defined as >=2 episodes in 6 months or >=3 in 12 months

›Microbiology

›Causative organisms

›Escherichia coli: 80-85% of uncomplicated cystitis cases

›Staphylococcus saprophyticus: 5-15% (young sexually active women)

›Klebsiella pneumoniae: 5-10%

›Proteus mirabilis: 2-5% (associated with struvite stones)

›Enterococcus faecalis: 1-5%

›Antimicrobial resistance trends

›E. coli TMP-SMX resistance: 10-25% in most US/European regions

›ESBL-producing E. coli increasing in community-acquired UTI

›Fluoroquinolone resistance: 15-20% in outpatient E. coli isolates

Pathophysiology

›Infection mechanism

›Ascending infection pathway

›Periurethral colonization from rectal or vaginal flora

›Ascent through urethra to bladder

›Adherence of uropathogenic E. coli to bladder urothelium via type 1 and P fimbriae

›Bladder defense mechanisms

›Washout with micturition

›Mucopolysaccharide layer (GAG layer) preventing bacterial adherence

›Tamm-Horsfall protein binding to type 1 fimbriae

›Innate immune response via Toll-like receptor 4 signaling

›Virulence factors

›UPEC (uropathogenic E. coli) virulence

›Type 1 fimbriae: bind mannose residues on uroplakins

›P fimbriae: bind globoside receptors; associated with pyelonephritis

›Alpha-hemolysin: epithelial cytotoxicity

›Aerobactin and siderophores: iron acquisition for growth

›Intracellular bacterial communities (IBCs)

›UPEC forms biofilm-like IBCs within superficial urothelial cells

›Protects from antibiotics and immune clearance

›Contributes to recurrent infection patterns

›Complicated vs uncomplicated distinction

›Uncomplicated cystitis

›Infection confined to bladder mucosa

›Healthy non-pregnant adult female without structural abnormalities

›Complicated cystitis

›Presence of complicating factors: catheter, obstruction, pregnancy, immunosuppression, male sex, structural abnormality

Therapeutic Considerations

›Antibiotic stewardship principles

›Empiric therapy selection based on local antibiogram

›Know local E. coli resistance patterns for TMP-SMX (use only if <20%)

›IDSA recommends nitrofurantoin as preferred agent due to low resistance

›Short-course therapy principle

›3-5 day courses equivalent to 7-day courses for uncomplicated cystitis

›Shorter courses reduce adverse effects, C. difficile risk, resistance selection

›ACP Best Practice Advice 2021: avoid longer than recommended courses

›Culture-directed vs empiric treatment

›Empiric treatment appropriate for classic uncomplicated cystitis in women

›Culture mandatory for all men, pregnant patients, recurrent UTI, treatment failure

›SCOUT trial evidence (Lancet 2026)

›Head-to-head comparison of antibiotic regimens for uncomplicated UTI in women

›Nitrofurantoin 100 mg BID x 5 days: highest clinical resolution (74%)

›Fosfomycin 3 g single dose: significantly inferior to nitrofurantoin

›Pivmecillinam 400 mg TID x 3 days: 70% clinical resolution

›Fosfomycin should not be promoted as equivalent to nitrofurantoin

›Non-antibiotic management evidence

›NSAIDs as monotherapy for uncomplicated cystitis (Cochrane 2024)

›Inferior to antibiotics; 27% of patients treated with NSAIDs alone develop pyelonephritis

›Not recommended as monotherapy; may be used as adjunctive analgesics

›Delayed prescribing strategy

›Backup prescription to fill if symptoms do not improve in 48-72 hours

›Reduces antibiotic use without increasing complication rates in select patients

›Appropriate for low-risk women who prefer to delay antibiotics

11Patient Discharge Instructions/pdi36

copy discharge instructions

›Discharge instructions for cystitis

›About your diagnosis

›You have been diagnosed with a bladder infection (cystitis)

›This is caused by bacteria growing in your bladder

›Most cases improve within 24-48 hours of starting antibiotics

›Your antibiotic prescription

›Take all doses as directed, even if you feel better early

›Do not save antibiotics for future use

›Take with food if stomach upset occurs

›Phenazopyridine (if prescribed for pain)

›This is a pain reliever for your bladder only — it is NOT an antibiotic

›Your urine will turn orange or red — this is expected and harmless

›Take for 2 days maximum only

›Fluids and self-care

›Drink at least 6-8 glasses of water per day

›Avoid caffeine, alcohol, and spicy foods until symptoms resolve

›Urinate promptly when you feel the urge — do not hold urine

›Symptom monitoring

›Symptoms should improve significantly within 48 hours

›If no improvement after 48-72 hours, call your doctor for reassessment

›Return to the emergency department immediately if you develop

›Fever greater than 38°C (100.4°F) or chills/rigors

›Pain in your back, flank, or side

›Nausea or vomiting that prevents you from taking your antibiotics

›Worsening symptoms or inability to urinate

›Confusion, dizziness, or feeling very unwell

›Prevention of future infections

12References/r19

Guidelines and key sources

›IDSA guidelines

›Gupta K, Hooton TM, Naber KG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: 2010 Update (IDSA/ESCMID). Clinical Infectious Diseases. 2011. doi:10.1093/cid/ciq257

›Core guideline for empiric antibiotic selection and duration

›Trautner BW, Cortés-Penfield NW, Gupta K, et al. IDSA 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections. Infectious Diseases Society of America. 2025

›Updated guidance for complicated UTI including ESBL and resistant organisms

›IDSA 2023 Guidance on Treatment of Antimicrobial Resistant Gram-Negative Infections. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad428

›Landmark trials and systematic reviews

›Hooton TM. Uncomplicated Urinary Tract Infection. New England Journal of Medicine. 2012. doi:10.1056/NEJMcp1104429

›Comprehensive clinical review of UTI diagnosis and management

›Llor C, et al. SCOUT trial: Clinical and Bacteriological Effectiveness of Three Short-Course Antibiotic Regimens and Single-Dose Fosfomycin for Uncomplicated UTIs in Women. Lancet. 2026. PMID:42026010

›Head-to-head RCT: nitrofurantoin superior to fosfomycin; pivmecillinam effective

›Kim DK, et al. Reappraisal of Treatment Duration of Antibiotic Regimens for Acute Uncomplicated Cystitis in Women: Systematic Review and Network Meta-Analysis of 61 RCTs. Lancet Infectious Diseases. 2020. PMID:32446327

›Sachdeva A, et al. NSAIDs for Treating Symptomatic Uncomplicated UTIs in Non-Pregnant Adult Women. Cochrane Database of Systematic Reviews. 2024. doi:10.1002/14651858.CD014762.pub2

›Clinical practice resources

›Kurotschka PK, Gágyor I, Ebell MH. Acute Uncomplicated UTIs in Adults: Rapid Evidence Review. American Family Physician. 2024. PMID:38393801

›Meddings J, Chrouser K, Fowler KE, et al. Ann Arbor Guide to Triaging Adults With Suspected UTI for In-Person and Telehealth Settings. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2025.56135

›Validated triage tool for telephone, telehealth, and in-person UTI management

›Lee RA, Centor RM, Humphrey LL, et al. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice from ACP. Annals of Internal Medicine. 2021. doi:10.7326/M20-7355

›Committee on Clinical Consensus-Obstetrics. Urinary Tract Infections in Pregnant Individuals. Obstetrics and Gynecology. 2023. doi:10.1097/AOG.0000000000005269

Learn More: Cystitis→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.